Health Care Activity
J&J’s Stelara Revenue Plummets as Biosimilar Competition Intensifies in 2025
Stelara; Johnson & Johnson; ustekinumab; biosimilars; revenue decline; Q2 2025; pharmacy benefit managers; formulary exclusion; drug pricing; autoimmune disease
Viome and Scripps Initiate AI-Powered At-Home RNA Test for Early Colon Cancer Risk Detection
Viome; Scripps Research; AI-powered diagnostics; RNA test; at-home colon cancer screening; colon polyps; clinical study; microbiome; early cancer detection
Recent Trends in Specialized Support to Accelerate Biotech Success (2025)
biotech support; CROs; advanced therapies; funding; risk management; strategic partnerships; operational efficiency
FDA Investigates Patient Deaths Linked to Sarepta’s Elevidys Gene Therapy for Duchenne Muscular Dystrophy
FDA; Sarepta; Elevidys; Duchenne muscular dystrophy; gene therapy; patient deaths; acute liver failure; liver toxicity; regulatory investigation; non-ambulatory patients
Hims & Hers Stock Plunges 30% as Novo Nordisk Ends Wegovy Sales Deal
Hims & Hers; stock plunge; Novo Nordisk; Wegovy; partnership termination; compounded GLP-1 drugs; deceptive marketing; telehealth; weight loss drugs
Lark Health Launches LarkVantage: AI-Powered Platform to Manage GLP-1 Costs
Lark Health; LarkVantage; GLP-1 cost management; AI healthcare; prior authorization; utilization management; PBM; health plans; weight management; Matthew Gibbs
Sarepta Halts Duchenne Gene Therapy in Some Patients After Second Death
Sarepta Therapeutics; gene therapy; Duchenne muscular dystrophy; Elevidys; acute liver failure; non-ambulatory patients; FDA; clinical trial pause; immunosuppression; patient safety
FDA Institutes Stricter, Targeted COVID Vaccine Policy, Moving Away from ‘One-Size-Fits-All’ Approach
FDA; COVID-19; vaccine policy; vaccine eligibility; clinical trials; high-risk groups; elderly; policy change; public health
Recent Developments in Building Robust Health System Partnerships for Life Sciences (2025)
health system partnerships; life sciences; strategic partnerships; digital transformation; artificial intelligence; cybersecurity; primary care; biotechnology; Salesforce Life Sciences Cloud; data integration
Novo Nordisk CEO Departs Amid Weight-Loss Drug Market Pressures; Flagship Biotech Appoints CEO from Scholar Rock
Novo Nordisk; CEO departure; Lars Fruergaard Jørgensen; obesity drugs; weight-loss market; Eli Lilly competition; market challenges; Flagship Biotech; CEO appointment; Scholar Rock